Literature DB >> 9875532

Degenerative terminals of the perforant pathway are human alpha-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease.

E Iseki1, W Marui, K Kosaka, H Akiyama, K Ueda, T Iwatsubo.   

Abstract

We investigated the hippocampal pathology in diffuse Lewy body disease (DLBD) using alpha-synuclein immunohistochemistry. Ubiquitin-positive intrahippocampal structures caused by the degeneration of terminal axons of the perforant pathway were observed to be alpha-synuclein immunoreactive. These alpha-synuclein-positive degenerative terminals contained granulo-filamentous or vesiculo-tubular components similar to those of Lewy bodies (LB) immunoelectron microscopically, suggesting that alpha-synuclein may abnormally aggregate into filamentous or membranous cytoskeletal components including neurofilaments and synaptic vesicles in DLBD. A 'dying back' degenerating process due to a blockage of axonal transport may explain why the degenerative terminals and LB share similar alpha-synuclein-positive components, but the origin cells of the perforant pathway contain only a few LB.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9875532     DOI: 10.1016/s0304-3940(98)00856-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

1.  Acyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism.

Authors:  Mikhail Y Golovko; Thad A Rosenberger; Nils J Faergeman; Søren Feddersen; Nelson B Cole; Ingrid Pribill; Johannes Berger; Robert L Nussbaum; Eric J Murphy
Journal:  Biochemistry       Date:  2006-06-06       Impact factor: 3.162

2.  Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders.

Authors:  Thomas G Beach; Charles H Adler; Lucia I Sue; Linda Vedders; Lihfen Lue; Charles L White Iii; Haru Akiyama; John N Caviness; Holly A Shill; Marwan N Sabbagh; Douglas G Walker
Journal:  Acta Neuropathol       Date:  2010-03-21       Impact factor: 17.088

3.  Diffuse Lewy Body Disease.

Authors:  Theresa A. Zesiewicz; Matthew J. Baker; Peter B. Dunne; Robert A. Hauser
Journal:  Curr Treat Options Neurol       Date:  2001-11       Impact factor: 3.598

4.  Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.

Authors:  J G Culvenor; C A McLean; S Cutt; B C Campbell; F Maher; P Jäkälä; T Hartmann; K Beyreuther; C L Masters; Q X Li
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

5.  Limbic lobe microvacuolation is minimal in Alzheimer's disease in the absence of concurrent Lewy body disease.

Authors:  Yasuhiro Fujino; Dennis W Dickson
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

6.  Evaluation of alpha-synuclein immunohistochemical methods used by invited experts.

Authors:  Thomas G Beach; Charles L White; Ronald L Hamilton; John E Duda; Takeshi Iwatsubo; Dennis W Dickson; James B Leverenz; Federico Roncaroli; Manuel Buttini; Christa L Hladik; Lucia I Sue; Joseph V Noorigian; Charles H Adler
Journal:  Acta Neuropathol       Date:  2008-07-15       Impact factor: 17.088

7.  Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction.

Authors:  Thomas G Beach; Charles H Adler; LihFen Lue; Lucia I Sue; Jyothi Bachalakuri; Jonette Henry-Watson; Jeanne Sasse; Sarah Boyer; Scophil Shirohi; Reed Brooks; Jennifer Eschbacher; Charles L White; Haru Akiyama; John Caviness; Holly A Shill; Donald J Connor; Marwan N Sabbagh; Douglas G Walker
Journal:  Acta Neuropathol       Date:  2009-04-28       Impact factor: 17.088

8.  Alpha-synuclein pathology in the olfactory pathways of dementia patients.

Authors:  Paul S Hubbard; Margaret M Esiri; Margaret Reading; Rupert McShane; Zsuzsanna Nagy
Journal:  J Anat       Date:  2007-06-06       Impact factor: 2.610

9.  Brain prostaglandin formation is increased by alpha-synuclein gene-ablation during global ischemia.

Authors:  Mikhail Y Golovko; Eric J Murphy
Journal:  Neurosci Lett       Date:  2007-12-23       Impact factor: 3.046

10.  Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.

Authors:  Negin Nouraei; Daniel M Mason; Kristin M Miner; Michael A Carcella; Tarun N Bhatia; Benjamin K Dumm; Dishaben Soni; David A Johnson; Kelvin C Luk; Rehana K Leak
Journal:  Exp Neurol       Date:  2017-10-19       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.